Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 2 |
2004 | 2 |
2005 | 1 |
2006 | 1 |
2014 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells.
J Infect Dis. 2004 Nov 1;190(9):1692-6. doi: 10.1086/424490. Epub 2004 Sep 30.
J Infect Dis. 2004.
PMID: 15478077
Statistical evaluation of HIV vaccines in early clinical trials.
Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND.
Moodie Z, et al.
Contemp Clin Trials. 2006 Apr;27(2):147-60. doi: 10.1016/j.cct.2005.11.008. Epub 2006 Jan 19.
Contemp Clin Trials. 2006.
PMID: 16426900
Item in Clipboard
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L.
Gilbert PB, et al.
J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1.
J Infect Dis. 2003.
PMID: 12854072
Item in Clipboard
Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network.
Gilbert PB, et al.
Vaccine. 2003 Jun 20;21(21-22):2933-47. doi: 10.1016/s0264-410x(03)00158-0.
Vaccine. 2003.
PMID: 12798637
Clinical Trial.
Item in Clipboard
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.
Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.
Frey SE, et al.
Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.
Clin Vaccine Immunol. 2014.
PMID: 25253665
Free PMC article.
Clinical Trial.
Item in Clipboard
Participant retention in clinical trials of candidate HIV vaccines.
de Bruyn G, Hudgens MG, Sullivan PS, Duerr AC.
de Bruyn G, et al.
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):499-501. doi: 10.1097/01.qai.0000148532.12329.df.
J Acquir Immune Defic Syndr. 2005.
PMID: 16010176
Item in Clipboard
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL.
Lee D, et al.
J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29.
J Infect Dis. 2004.
PMID: 15295694
Clinical Trial.
Item in Clipboard
Cite
Cite